Press Release

Shionogi Filed for the New Drug Application of Baloxavir Marboxil in Taiwan for the Treatment of Influenza

OSAKA, Japan, July 2, 2018 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that Shionogi filed the New Drug Application (NDA) of baloxavir marboxil in Taiwan for the treatment of influenza in patients 12 years of age and older on June 29, 2018.

Baloxavir marboxil has a novel mechanism of action that inhibits cap-dependent endonuclease, an essential enzyme for viral replication. Baloxavir marboxil was approved in Japan on February 23, 2018 and is available under the brand name XOFLUZA™ for the treatment of influenza Types A and B in adults and pediatric patients.¹ Clinical efficacy and safety data from a phase II study in Japan and a global phase III study (CAPSTONE-1) in otherwise healthy patients supported this NDA.

Shionogi and F. Hoffmann-La Roche Ltd. (hereafter “Roche”) are in a license and collaboration agreement to further develop and commercialize baloxavir marboxil. Under the terms of this agreement, Roche holds worldwide rights to baloxavir marboxil excluding Japan and Taiwan where the rights are retained exclusively by Shionogi. Shionogi is currently conducting a global Phase III study (CAPSTONE-2) in individuals at high risk for influenza-related complications.

Shionogi's research and development efforts target infectious diseases as one of its priority areas, and Shionogi has positioned “protecting people from the threat of infectious diseases” as one of its core social missions. Shionogi strives constantly to bring forth innovative drugs for the treatment of infectious diseases, to protect the health of the many patients we serve.
About Baloxavir Marboxil
Baloxavir marboxil, discovered by Shionogi, has a novel mechanism of action that inhibits cap-dependent endonuclease, an essential enzyme for viral replication. The proposed regimen for baloxavir marboxil is a single-oral dose to treat influenza, which is different from currently available antiviral treatments. In non-clinical studies, baloxavir marboxil demonstrated an antiviral effect against a wide range of influenza viruses including oseltamivir-resistant strains and avian strains (H7N9, H5N1).2,3,4

About CAPSTONE-1 Study
The CAPSTONE-1 study was a randomized, double-blind, multicenter, parallel-group, placebo- and active-controlled study that enrolled 1,436 otherwise healthy patients diagnosed with influenza. In this study, baloxavir marboxil significantly reduced the time to alleviation of symptoms compared with placebo (median time; 53.7 hours versus 80.2 hours; p<0.0001). Baloxavir marboxil also significantly reduced time to cessation of infectious viral shedding compared with both placebo and oseltamivir (median time of viral shedding; 24.0 hours for baloxavir marboxil, 96.0 hours for placebo, 72.0 hours for oseltamivir; p<0.0001). Additionally, baloxavir marboxil was generally well tolerated with a numerically lower overall incidence of adverse events reported compared with both placebo and oseltamivir (incidence of adverse events; 20.7% for baloxavir marboxil, 24.6% for placebo, 24.8% for oseltamivir). The study design and key findings from the CAPSTONE-1 study are summarized in the press releases issued on September 13 and October 5, 2017.5,6

About Influenza
Seasonal, epidemic and pandemic influenza remain a major public health concern, and novel influenza drugs that will offer significant improvement over current therapy are urgently needed. Globally, annual epidemics result in 3 to 5 million cases of severe disease, millions of hospitalizations and up to 650,000 deaths worldwide.7,8,9,10,11 In general, those at highest risk of influenza-related complications include children under 2 years of age, adults over 65 years of age, pregnant women, and people of any age with certain medical conditions, including chronic heart, lung, metabolic diseases (such as diabetes) and weakened immune systems.12
In Taiwan, approximately 14% of the population need treatments for influenza or related pneumonia every year.13 The influenza epidemic period occurs in the winter, from late November through March. The overall health impact (e.g., infections, hospitalizations, and deaths) of a flu season varies from year to year. Taiwan CDC monitors circulating flu viruses and their related disease activity and provides influenza reports (Influenza Express) each week from October through May. In Taiwan, among outpatient cases of influenza, about 0.5% require hospitalization, of which 7% of the patients with serious complications need intensive care, and of which the mortality rate is about 20%.14
About Shionogi
Shionogi & Co., Ltd. is a Japanese major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, cardiovascular diseases and gastroenterology. Our pipeline is focused on infectious disease, pain, CNS and oncology. For more information on Shionogi & Co., Ltd., visit www.shionogi.co.jp/en.
Taiwan Shionogi & Co., Ltd was incorporated locally in Taiwan in 1964. It is a wholly owned subsidiary, and also the oldest subsidiary of Shionogi & Co., Ltd, headquartered in Osaka, Japan. Taiwan Shionogi has long history of developing drugs especially in the field of antibiotics and anti-infective agents to save the lives and wellbeing of patients. Under the corporate mission, Taiwan Shionogi continuously strives to save the lives of patients and improving their quality of life by providing better medicines. In addition to the sales expansion of Flumarin®, Finibax®, Pirespa®, and Rapiacta®, Taiwan Shionogi is making its best efforts to introduce new drugs and aiming at contributing to the medium-and-long term growth of the Shionogi Group.

Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885

References
1.  Press release on March 14, 2018
    XOFLUZA (Baloxavir Marboxil) Tablets 10mg/20mg for the Treatment of Influenza Types A and B launched in Japan
2.  T. Noshi et al. S-033447/S-033188, a Novel Small Molecule Inhibitor of Cap-dependent
Endonuclease of Influenza A and B Virus: In Vitro Antiviral Activity against Laboratory Strains of Influenza A and B Virus in Madin-Darby Canine Kidney Cells. Poster presentation at OPTIONS IX, August 2016.


5. Press release on September 13, 2017
S-033188 Phase 3 CAPSTONE-1 Study Results for Treatment of Influenza Presented at the European Scientific Working Group on Influenza Conference

6. Press release on October 5, 2017
SHIONOGI TO PRESENT S-033188 PHASE 3 CAPSTONE-1 STUDY RESULTS FOR TREATMENT OF INFLUENZA AT IDWEEK 2017

7. [Web Link]
World Health Organization website, Up to 650 000 people die of respiratory diseases linked to seasonal flu each year, Accessed December 14, 2017.

8. [Web Link]


10. [Web Link]


12. [Web Link]

13. [Web Link]
Taiwan CDC website, Practical Guideline for Prevention and Control of Seasonal Influenza, December 2017.

14. [Web Link]
Taiwan CDC website, Influenza (Flu), Accessed November 25, 2014.